GENERIC NAME: trastuzumab
BRAND NAME: Herceptin
GENERIC AVAILABLE: No
- Trastuzumab is used for preventing recurrence (adjuvant treatment) of HER2 overexpressing breast cancer. It is also used for metastatic breast cancer or metastatic gastric or gastroesophageal junction adenocarcinoma among patients who overexpress HER2. It may be used alone or combined with other chemotherapeutic drugs.
WARNING: (BLACK BOX WARNING)
Trastuzumab can cause heart failure, especially when it is combined with anthracycline-containing chemotherapy regimens. Left ventricular function should be monitored prior to and during treatment. Trastuzumab should be stopped in patients receiving adjuvant therapy, and withheld in patients with metastatic disease if the function of the heart decreases significantly.
Trastuzumab can cause serious and fatal infusion reactions and pulmonary toxicity. Symptoms usually occur during treatment or within 24 hours of treatment. The infusion should be interrupted if patients develop shortness of breath or significant reduction in blood pressure, and patients should be monitored until symptoms completely resolve.
Trastuzumab should be stopped if any of the following occurs
Use of trastuzumab during pregnancy can cause oligohydramnios and oligohydramnios sequence, manifesting as pulmonary hypoplasia, skeletal abnormalities, and death of the baby.
Quick GuidePancreatic Cancer Symptoms, Causes, and Treatment
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Need help identifying pills and medications?
Use the pill identifier tool on RxList.